ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO824

Biological Parameters in Biopsy-Proven Renal Thrombotic Microangiopathies

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Halimi, Jean-Michel, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre-Val de Loire, France
  • Maisons, Valentin, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre-Val de Loire, France
  • Chardon, Etienne, INSERM U1327, Tours, Centre-Val de Loire, France
  • Caillard, Sophie, Universite de Strasbourg, Strasbourg, Grand Est, France
  • Frimat, Marie, Universite de Lille, Lille, Hauts-de-France, France
  • Mesnard, Laurent, Hopital Tenon, Paris, Île-de-France, France
  • Chauvet, Sophie, Hopital Europeen Georges Pompidou Cancerologie, Paris, France
  • Piver, Eric, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre-Val de Loire, France

Group or Team Name

  • MATRIX Consortium Cohort Study (NCT05991245).
Background

Thrombotic microangiopathies (TMA) are suspected in the presence of anemia, high LDH, low haptoglobin, thrombocytopenia and schistocyte>1%. The kidney is the most frequently affected organ. However, interpreting biological parameters in this context is unclear.

Methods

Biological parameters were studies in 967 patients with biopsy-proven renal TMA from 25 French hospitals during the 2009-2023 period.

Results

Median age was 49 (IQR: 36-64), 53.2% were male. All TMA KDIGO causes were represented. Biomarker sensitivity (ie. proportion of patients with the parameter) ranked as follows: anaemia (81.7%), high LDH (75.4%), low haptoglobin (53.7%), thrombocytopenia (40.3%), schistocytes>1% (34.0%) but varied widely according to fibrinogen, prothrombin time (PT) and serum creatinine. The sensitivity of these biological parameters was preserved (>75%) only in patients with both fibrinogen levels <5 g/L and serum creatinine ≥300 µmol/L, ie 29% of the population.
Laboratories used 11 different ways to report schistocytosis: various threshold values and reporting (binary, qualitative, semi-quantitative, quantitative, adjective-based vs numerical) were found. Schistocyte>1% had been used as the sole criterion, suspicion of TMA would have been missed in 66.0% of patients (23.8% to 86.4% according to TMA causes).
Unsupervised cluster analysis revealed that biological parameter structuring is strongly linked to specific renal TMA causes. Using fibrinogen, serum creatinine, anemia, LDH and haptoglobin, A simple algorithm identified patients with infrequent (sensitivity <10%) or very frequent (sensitivity: 75-90%) phenotypes.

Conclusion

Schistocyte reporting varies widely and “schistocyte>1%” misses two-thirds of renal TMAs. Biological parameters’ results should be interpreted according to fibrinogen, creatinine and PT but careful analysis of these parameters can help differentiate among TMA causes. A simple algorithm provides crucial information regarding the necessity of kidney biopsy, indicating when renal TMA is either unlikely or highly probable.